These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 24407578)

  • 41. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
    Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
    Ziai D; Wagner T; El Badaoui A; Hitzel A; Woillard JB; Melloni B; Monteil J
    Cancer Imaging; 2013 Mar; 13(1):73-80. PubMed ID: 23466871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
    Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI.
    Stojiljkovic M; Sobic Saranovic D; Odalovic S; Popovic M; Petrovic J; Rankovic N; Veljkovic M; Artiko V
    Radiol Oncol; 2022 Dec; 56(4):453-460. PubMed ID: 36317553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and prognostic value of
    Albano D; Zizioli V; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):87-93. PubMed ID: 30573388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.
    Chiu KWH; Lam KO; An H; Cheung GTC; Lau JKS; Choy TS; Lee VHF
    BMC Cancer; 2018 Jul; 18(1):776. PubMed ID: 30064385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early evaluation of tumor response to
    Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
    Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Defining the priority of using 18F-FDG PET for recurrent cervical cancer.
    Yen TC; See LC; Chang TC; Huang KG; Ng KK; Tang SG; Chang YC; Hsueh S; Tsai CS; Hong JH; Lin CT; Chao A; Ma SY; Lin WJ; Fu YK; Fan CC; Lai CH
    J Nucl Med; 2004 Oct; 45(10):1632-9. PubMed ID: 15471826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
    Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value of
    Tang S; Zhang Y; Li Y; Zhang Y; Xu Y; Ding H; Chen Y; Ren P; Ye H; Fu S; Lin S
    Front Immunol; 2023; 14():1034416. PubMed ID: 36860861
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
    Önner H; Eren OÖ; Körez MK; Yilmaz F; Kara Gedik G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):319-324. PubMed ID: 37030597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix.
    Chung HH; Cheon GJ; Kim JW; Park NH; Song YS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1862-1869. PubMed ID: 28534183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.